SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Trevena to Participate in Upcoming Conferences in June 2019
[May 29, 2019]

Trevena to Participate in Upcoming Conferences in June 2019


CHESTERBROOK, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System conditions, today announced that Carrie Bourdow, President and Chief Executive Officer, and Mark Demitrack, SVP and Chief Medical Officer, will present at two upcoming conferences:

  • 2019 BIO International Convention, sponsored by the Biotechnology Innovation Organization, to be held at the Philadelphia Convention Center in Philadelphia, PA on Wednesday, June 5, 2019 at 3:45pm ET.

    Live audio webcast and archived replay of the presentation will be available on the Company’s investor relations website at https://investors.trevena.com/. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.

  • JMP Securities Life Sciences Conference, sponsored by JMP Securities, to be held at The St. Regis New York in New York City on June 20, 2019 t 1:30pm ET.



For more information about the conferences, or to schedule a one-on-one meeting with the Company’s management, please contact KCSA Strategic Communications at Trevena@kcsa.com, or send an email to biopartnering@bio.org (2019 BIO International Convention), or kweisgerber@ljfevents.com (JMP Securities Life Sciences Conference). 

About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System conditions.  The Company has four novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the acute treatment of migraine, and TRV734 for maintenance treatment of opioid use disorder.  The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain.


For more information, please contact:

Investor Contact:
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1254 / 212-896-1267
Email: IR@trevena.com  

Company Contact:
Bob Yoder, SVP and Chief Business Officer
Trevena, Inc.
Phone: 610-354-8840

Primary Logo


[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy